Spasmomen® (Tablets) Instructions for Use
Marketing Authorization Holder
A.Menarini Industrie Farmaceutiche Riunite, S.r.l. (Italy)
Manufactured By
Berlin-Chemie, AG (Germany)
ATC Code
A03AB06 (Otilonium bromide)
Active Substance
Otilonium bromide (Rec.INN registered by WHO)
Dosage Form
| Spasmomen® | Film-coated tablets, 40 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white or almost white, round, biconvex.
| 1 tab. | |
| Otilonium bromide | 40 mg |
Excipients: lactose monohydrate – 28 mg, rice starch – 29 mg, sodium carboxymethyl starch – 2 mg, magnesium stearate – 1 mg.
Film coating composition: hypromellose – 1.25 mg, titanium dioxide – 0.5 mg, macrogol – 0.5 mg, talc – 0.25 mg.
10 pcs. – blister packs (3) – cardboard packs.
Clinical-Pharmacological Group
Myotropic antispasmodic
Pharmacotherapeutic Group
Spasmolytic agent
Pharmacological Action
Otilonium bromide – the active substance of the drug Spasmomen® – is a myotropic antispasmodic: it reduces the tone of the smooth muscles of the gastrointestinal tract.
The mechanism of action is due to the ability of otilonium bromide to influence the transport of Ca2+ ions in the intra- and extracellular space, as well as to block Ca2+ channels, muscarinic and tachykinin receptors.
The combination of properties of a Ca2+ channel blocker and a moderately pronounced antimuscarinic action explains the pharmacological action of otilonium bromide.
Pharmacokinetics
Absorption
After oral administration, Otilonium bromide is absorbed from the gastrointestinal tract in a very small amount (3%), which is why the plasma concentration of the drug is very low.
Distribution
High degree of distribution in the smooth muscles of the rectum.
Elimination
Most of the absorbed drug is excreted through the bile ducts (95-97%).
Indications
- Spastic conditions, dyskinesias (hyperkinetic type) of the gastrointestinal tract (esophagitis, gastritis, duodenitis, enteritis, irritable bowel syndrome);
- Preparation of patients for endoscopic examination of the gastrointestinal tract.
ICD codes
| ICD-10 code | Indication |
| K20 | Esophagitis |
| K29 | Gastritis and duodenitis |
| K52 | Other noninfectious gastroenteritis and colitis |
| K58 | Irritable bowel syndrome |
| ICD-11 code | Indication |
| DA24.Z | Unspecified esophagitis |
| DA42.81 | Radiation gastritis |
| DA42.8Z | Gastritis due to external causes, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.53 | Radiation duodenitis |
| DA51.5Z | Duodenitis due to external causes, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DB33.2Z | Allergic or alimentary colitis, unspecified |
| DB33.4Y | Other specified colitis or proctitis caused by external agents |
| DB33.4Z | Colitis or proctitis caused by external agents, unspecified |
| DD91.0Z | Irritable bowel syndrome, unspecified |
| DE2Z | Diseases of the digestive system, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer Spasmomen® orally.
Swallow the tablet whole with a sufficient amount of water.
The standard adult dosage is one tablet (40 mg) taken two to three times daily.
Adhere to the prescribed dosage and frequency as directed by a physician.
For preparation prior to gastrointestinal endoscopic procedures, follow the specific instructions provided by the healthcare professional.
Do not exceed the recommended daily dose.
The duration of therapy is determined by the treating physician based on the clinical indication and patient response.
Efficacy and safety data for the use of otilonium bromide in the pediatric population are not established.
The drug is contraindicated in children under 3 years of age.
Adverse Reactions
When taking the drug Spasmomen® in therapeutic doses, no side effects were detected, in particular, the drug does not cause atropine-like reactions.
In rare cases, allergic reactions are possible.
Contraindications
- Hypersensitivity to otilonium bromide or other components of the drug;
- Children under 3 years of age.
With caution: glaucoma; pyloric stenosis; prostatic hyperplasia.
Use in Pregnancy and Lactation
Data from preclinical studies show the absence of teratogenic and mutagenic effects of the drug, but its use during pregnancy and lactation is possible only if the intended benefit to the mother outweighs the possible risk to the fetus or child.
Pediatric Use
Contraindicated in children under 3 years of age.
Data on the efficacy and safety of otilonium bromide in children are not available.
Special Precautions
Effect on the ability to drive vehicles and mechanisms
There have been no reports of a negative effect of the drug on the ability to drive vehicles and operate machinery.
Overdose
Since the drug is practically non-toxic, no cases of overdose have been reported. In case of overdose, treatment should be symptomatic and supportive.
Drug Interactions
Not known.
Storage Conditions
The drug should be stored out of the reach of children at a temperature not exceeding 30°C (86°F).
Shelf Life
Shelf life – 3 years.
Dispensing Status
Over-the-counter.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Picamilon pills 50mg, 60pcs
Ingavirin capsules 90mg, 10pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Fenotropil pills 100mg, 60pcs
Belosalic, lotion solution for external use spray 100ml
Arbidol, capsules 100mg, 40pcs
Phenibut-Vertex pills 250mg, 20pcs
Mildronate capsules 500mg, 90pcs
Actovegin pills 200mg, 50pcs
Nootropil pills 800mg, 30pcs
Kagocel pills 12mg, 30pcs
Daivobet, ointment, 30g
Cavinton Comfort, dispersible pills 10mg 90pcs
OKI, sachets 80mg 2g, 12pcs 